active-semi® Releases First New High-Performance Integrated Intelligent BLDC Motor Controller and Driver with 150MHz Arm® Cortex®-M4F MCU
active-semi®, Inc. (www.active-semi.com) announced today the first member of a new family of PAC® high-performance motor controllers with the PAC5523 IC. It is supported by an Evaluation Kit (EVK) and accompanying firmware for easy and fast evaluation of advanced motor control solutions.
The new PAC5523 contains the highest-performance MCU found in an integrated motor control and driver product on the market. It contains a 150MHz Arm® Cortex®-M4F MCU with 128kB FLASH, 32kB SRAM and an integrated Floating Point Unit (FPU) with Digital Signal Processor (DSP) instructions for highly efficient implementation of motor control and drive applications. The MCU also contains 4-level code protection, a cache for high-speed FLASH access, ECC for SRAM data and a CRC engine.
The PAC5523 also integrates highly-optimized peripherals specifically designed for BLDC motor control applications.
The 70V PAC5523 is optimized for battery-powered and other BLDC applications up to 48V. Integrated with the high-performance MCU is the power management, gate drivers and signal-conditioning for 3-phase inverter applications. The PAC5523 may be directly supplied with a battery of up to 20 or higher voltages using the 70V DC/DC Buck or SEPIC controller Multi-Mode Power ManagerTM (MMPM). The PAC5523 implements a Total Hibernate ModeTM which manages battery life and system efficiency by reducing quiescent current to 18uA.
The Application-Specific Power DriversTM (ASPD) integrates 70V/1.5A gate drivers for high power applications with 2-level dead-time protection for the external MOSFET-based inverter. The Configurable Analog Front-EndTM (CAFE) contains 3 Differential Programmable Gain Amplifiers (PGAs), 4 single-ended PGAs, 10 comparators, buffers and DACs that can be used for signal sampling and filtering for the control applications, minimizing the need for external components.
“The PAC5523 contains both a high-performance and high-memory MCU with integrated 70V DC/DC Controller and Gate Drivers, configurable analog front-end, coupled with active-semi®’s Total Hibernate Mode™ and other patented features, delivers the highest-performing and smallest system design at the highest system efficiency,” says David Briggs, Vice-President and General Manager at active-semi®. “We are excited about the rapidly expanding customer base that is now ramping into production with PAC5523.”
In a small 6mm x 6mm QFN package with all of the integration, the PAC5523 can realize an extremely small BOM and physical design size for compact BLDC battery-powered applications.
The PAC5523EVK extends the PAC® family of evaluation kits (EVKs) enabling fast prototyping for various applications including power tools, garden tools, telecom fans, battery-powered vehicles, drones, radio controlled cars, and general-purpose BLDC applications. Along with active-semi®’s motor control firmware and IP library, the PAC5523 will simplify system development with sensored and sensorless FOC and sensorless trapezoidal motor control applications for high-voltage battery powered applications.
PAC5523 IC and PAC5523EVK1 are available from leading distributors.
For more information on active-semi® and Intelligent Motor Control solutions, visit https://active-semi.com/products/intelligent-motor-control.
About active-semi ®
Founded in 2004 in Silicon Valley and headquartered in Dallas, Texas, active-semi® is a rapidly emerging leader in multi-billion-dollar power management and intelligent digital motor drive IC markets. The company’s portfolio of analog and mixed signal SoCs provide scalable core platforms used in charging, powering and embedded digital control systems for industrial, commercial and consumer applications. active-semi® offers Power Application Controllers® (PAC®), DC-DC and ActivePMU™ products that significantly reduce solution size and cost, improve system reliability, and shorten system development cycle-time.
active-semi® is a multi-national company with over 170 patents granted and pending. active-semi® International Inc. is a Cayman Island corporation backed by leading Venture Capital firms, including USVP, Tenaya Capital, LG and LDV Partners.
More information at www.active-semi.com
Bernd Krafthoefer, +1-214-453-1422
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
XINHUANET: Promotion Event of The Most Beautiful Shooting Location in China Held During Cannes Film Festival25.5.2019 18:20:00 CEST | Pressemelding
On May 16 (local time), an event was held at the 72nd Cannes Film Festival to recommend China’s most beautiful shooting locations on the theme of “Fascinating China.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190525005008/en/ The representative from Cannes Convention Bureau (1st L), Michel Chevillon (C), vice president of the French Riviera Chamber of Commerce and Industry and head of hotel association, and Adeline CHAUVEAU (3rd R), officer in charge of film and television projects from French Embassy to China, pose for a group photo with the representatives from the cities awarded for "The most beautiful shooting location in China." (Photo: Business Wire) In the event, the Yellow Sea National Forest Park in Dongtai, Jiangsu Province, the One Hundred Mile Azalea Forest in Bijie, Guizhou Province, Siming District of Xiamen, Fujian Province, and the Li Autonomous County in Lingshui, Hainan Province were on the list. The p
Knopp Biosciences Presents Positive Preclinical Data for Lead Neonatal Epilepsy Drug Candidate at 2019 Antiepileptic Drug and Device Trials XV Conference24.5.2019 14:00:00 CEST | Pressemelding
Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need, today presented in vitro and in vivo data for the company’s lead molecule for the targeted treatment of KCNQ2-neonatal epileptic encephalopathy (KCNQ2-NEE) at the Antiepileptic Drug and Device Trials XV Conference in Miami, Florida. KCNQ2-NEE, a rare infant genetic epilepsy, results from mutations in genes encoding the Kv7.2/Kv7.3 ion channel, leading to frequent seizures and profound developmental delay. The preclinical data were presented by Steven Dworetzky, Ph.D., Knopp’s Chief Scientific Officer, a longtime Kv7 researcher who led the group that first cloned the Kv7.2 and Kv7.3 genes during his former tenure with the Bristol-Myers Squibb Co. Dr. Dworetzky presented results demonstrating the in vitro nanomolar activity of KB-3061 and its significant seizure protection in the maximal electroshock mo
Accelerate Your Business in South Korea Through 2019 K-Startup Grand Challenge24.5.2019 10:20:00 CEST | Pressemelding
Entrepreneurs from across the globe should set their sights on participating in the 2019 K-Startup Grand Challenge. Supported by the Ministry of SMEs and Startups and National IT Industry Promotion Agency (NIPA) of South Korea, the initiative provides invaluable support and comprehensive resources to early age startups. Applications for the K-Startup Grand Challenge are currently being accepted through June 14, 2019. In order to advance in the program, teams must pass a regional audition. A judging panel of startup ecosystem experts and Korean accelerators will select 40 teams to participate in an enriching 3.5 month-long acceleration program in Korea. The selected teams will have exclusive access to free office space at the Startup Campus in Pangyo Techno Valley, one-on-one mentoring, information sessions, coaching on Korean and Asian business culture and the chance to attend insightful seminars on accounting regulations to tax laws, patents and more. Opportunities for networking with
New Investigational Clinical Data for Ipsen’s Oncology Products in 11 Solid Tumor Types to Be Presented at 2019 ASCO Annual Meeting24.5.2019 05:00:00 CEST | Pressemelding
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that new data from clinical studies on investigational uses of cancer medicines cabozantinib (Cabometyx®), liposomal irinotecan (Onivyde®), and lanreotide autogel (Somatuline®, marketed as Somatuline Depot® in the United States) will be presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting takes place in Chicago, Illinois, U.S., 31 May–4 June 2019; data featuring Ipsen medicines includes: New data from the Phase 3 CELESTIAL trial on the association of adverse events with efficacy outcomes for cabozantinib in patients with advanced hepatocellular carcinoma Overview of the Phase 3 COSMIC-312 trial of cabozantinib in combination with atezolizumab vs sorafenib in patients with advanced hepatocellular carcinoma who have not received previous systemic anticancer therapy First Phase 2 data from the CaboGIST study (trial 1317) from the European Organization for Research and Treatment of
The Posiflex Group Showcases an Ecosystem of Connected Solution Endpoints with IoT Remote Monitoring at Computex 201924.5.2019 01:00:00 CEST | Pressemelding
For the Computex 2019 show, The Posiflex Group is featuring leading solution technology from the family of brands as a fully Serviced IoT Ecosystem. Solution end points include: Connected Modular Kiosks, POS Terminals, and Digital Signage solutions from Posiflex and KIOSK Information Systems Smart Medical Displays with gesture controls from Portwell Connected Gaming Solutions with Player Tracking Technology from Portwell subsidiary, Ganlot The booth display is based on common field service endpoints represented in a European Manor Destination Resort setting. Field solutions for an array of vertical market applications include QSR ordering, cinema ticketing, fashion retail customer loyalty, interactive signage, hotel / medical center check-in and bill pay, as well as casino gaming technology. This year, in addition to their renowned POS product suite, Posiflex will be featuring newly introduced Modular Kiosk platforms (co-designed by KIOSK and Posiflex), which are configure-to-order sta
Audi China President Thomas Owsianski to Keynote at CES Asia 201923.5.2019 20:00:00 CEST | Pressemelding
The Consumer Technology Association (CTA)TM today announced that Thomas Owsianski, president of Audi China, will deliver a keynote address at the upcoming CES Asia 2019. Now in its fifth year, CES Asia will run June 11-13, 2019 at the Shanghai New International Expo Centre (SNIEC) in Shanghai, China. Thomas Owsianski’s keynote is scheduled for 4 PM, Tuesday, June 11, where he will unveil Audi’s vision in transforming mobility from a driving experience to a digital adventure. Mr. Owsianski joined the top management team of Audi China in August 2018 and was named President in October 2018. “Audi has been at the forefront of driving global transformation in the automotive industry through their breakthrough advancements in technology,” said Karen Chupka, executive vice president, CES. “Innovation has revolutionized the transportation experience, and we welcome Mr. Owsianski to the CES Asia stage to share Audi’s vision for the future of global mobility.” Throughout Asia and beyond, technol